Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

被引：4

作者：

Nettis E. ^{[1
]}

Masciopinto L. ^{[1
]}

Di Leo E. ^{[2
]}

De Candia N. ^{[3
]}

Albanesi M. ^{[1
]}

Di Bona D. ^{[1
]}

Quaranta N. ^{[3
]}

Macchia L. ^{[1
]}

机构：

[1] Department of Emergency and Organ Transplantation, School of Allergology and Clinical Immunology, University of Bari Aldo Moro, Policlinico Di Bari, Bari

[2] Section of Allergy and Clinical Immunology, Unit of Internal Medicine – “F. Miulli” Hospital, Acquaviva Delle Fonti, Bari

[3] Department of Neuroscience and Sensory Organs, Otolaryngology Unit, University of Bari Aldo Moro, Policlinico Di Bari, Bari

来源：

Clinical and Molecular Allergy | / 19卷 / 1期

关键词：

Asthma; Monoclonal antibody; Nasal polyps; Precision medicine; Rhinoconjuctivitis;

D O I：

10.1186/s12948-021-00144-x

中图分类号：

学科分类号：

摘要：

Background: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. Case presentation: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Conclusions: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint. © 2021, The Author(s).

引用

共 50 条

[21] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
James E. Frampton
Hannah A. Blair
American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
[22] Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
Rial Prado, Manuel Jorge
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2018, 28 (06) : 420 - 421
[23] Staphylococcus species induce a type-2 response in an subgroup of atopic dermatitis patients
Pospich, R.
Werfel, T.
Roesner, L.
ALLERGOLOGIE, 2023, 46 (02) : 136 - 137
[24] Efficacy and safety of dupilumab in children aged 6 months to 5 years with atopic dermatitis with and without type 2 comorbidities
Boguniewicz, M.
Sher, L.
Paller, A. S.
Chen, Z.
Shah, P.
Marco, A. Rodriguez
ALLERGY, 2023, 78
[25] IgE Autoantibodies in Atopic Dermatitis are associated with Type 2 Comorbidities and the atopic March
Krohn, Kortekaas, I
Badloe, F. M. S.
Herrmann, N.
Maintz, L.
De Vriese, S.
Ring, J.
ALLERGOLOGIE, 2024, 47 (07) : 383 - 386
[26] Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Ferrucci, Silvia
Casazza, Giovanni
Zussino, Martina
Tavecchio, Simona
Marzano, Angelo V.
Tedeschi, Micol
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
[27] Comparison of response between adults and adolescents in patients with severe atopic dermatitis treated with dupilumab
Mastorino, Luca
Vecco, Cristina
Cantafio Duo, Vania L.
Panzone, Michele
Gelato, Federica
Gallo, Giuseppe
Merli, Martina
Pala, Valentina
Quaglino, Pietro
Ribero, Simone
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2023, 158 (04) : 362 - 363
[28] IMPROVEMENT OF SEVERE ATOPIC DERMATITIS AND POST-INFLAMMATORY HYPERPIGMENTATION IN A HISPANIC PATIENT TREATED WITH DUPILUMAB
Delgado Guzman, T.
Chavez Ruiz, A.
Gonzalez-Diaz, S.
De Lira-Quezada, C.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S155 - S156
[29] Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
Adrien Maudinet
Sandrine Law-Koune
Claire Duretz
Audrey Lasek
Philippe Modiano
Thi Ha Chau Tran
Ophthalmology and Therapy, 2019, 8 : 485 - 490
[30] FACIAL ERYTHEMA IN SEVERE ATOPIC DERMATITIS PATIENTS TREATED WITH DUPILUMAB
Ahn, Jiyoung
Lee, Dong Heon
Na, Chan Ho
Shim, Dong Hyun
Choi, Yu Sung
Jung, Hye Jung
Simpson, Eric L.
ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 26 - 26

← 1 2 3 4 5 →